Nai‐Jen Hou

1.5k total citations
38 papers, 1.1k citations indexed

About

Nai‐Jen Hou is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Nai‐Jen Hou has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hepatology, 35 papers in Epidemiology and 3 papers in Rheumatology. Recurrent topics in Nai‐Jen Hou's work include Hepatitis C virus research (36 papers), Liver Disease Diagnosis and Treatment (34 papers) and Hepatitis B Virus Studies (24 papers). Nai‐Jen Hou is often cited by papers focused on Hepatitis C virus research (36 papers), Liver Disease Diagnosis and Treatment (34 papers) and Hepatitis B Virus Studies (24 papers). Nai‐Jen Hou collaborates with scholars based in Taiwan and United States. Nai‐Jen Hou's co-authors include Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang, Jee‐Fu Huang, Ming‐Yen Hsieh, Liang‐Yen Wang, Ming‐Yuh Hsieh, Zu‐Yau Lin, Shinn‐Cherng Chen and Wen‐Yu Chang and has published in prestigious journals such as PLoS ONE, Hepatology and Scientific Reports.

In The Last Decade

Nai‐Jen Hou

38 papers receiving 1.1k citations

Peers

Nai‐Jen Hou
Valeria Piazzolla Italy
Li‐Po Lee Taiwan
Hung‐Da Tung Taiwan
Annarosa Cussigh Italy
Sara Cmet Italy
Jennifer E. Layden‐Almer United States
Elisabetta Degasperi Italy
Guido Colloredo Italy
R. Soffredini Italy
Elisa Fumolo Italy
Valeria Piazzolla Italy
Nai‐Jen Hou
Citations per year, relative to Nai‐Jen Hou Nai‐Jen Hou (= 1×) peers Valeria Piazzolla

Countries citing papers authored by Nai‐Jen Hou

Since Specialization
Citations

This map shows the geographic impact of Nai‐Jen Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nai‐Jen Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nai‐Jen Hou more than expected).

Fields of papers citing papers by Nai‐Jen Hou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nai‐Jen Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nai‐Jen Hou. The network helps show where Nai‐Jen Hou may publish in the future.

Co-authorship network of co-authors of Nai‐Jen Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Nai‐Jen Hou. A scholar is included among the top collaborators of Nai‐Jen Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nai‐Jen Hou. Nai‐Jen Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jang, Tyng‐Yuan, Yi‐Hung Lin, Po‐Cheng Liang, et al.. (2022). Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes. The Kaohsiung Journal of Medical Sciences. 38(9). 897–906. 4 indexed citations
2.
Jang, Tyng‐Yuan, Chung‐Feng Huang, Ming‐Lun Yeh, et al.. (2021). Serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. The Kaohsiung Journal of Medical Sciences. 38(3). 261–267. 5 indexed citations
3.
Huang, Jee‐Fu, Chia‐Yen Dai, Chung‐Feng Huang, et al.. (2021). First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. Hepatology International. 15(5). 1136–1147. 40 indexed citations
4.
Jang, Tyng‐Yuan, Ching‐I Huang, Ming‐Lun Yeh, et al.. (2019). Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. Journal of Gastroenterology and Hepatology. 35(3). 473–481. 7 indexed citations
5.
Tsai, Pei‐Chien, Ta‐Wei Liu, Meng‐Hsuan Hsieh, et al.. (2016). A real‐world impact of cost‐effectiveness of pegylated interferon/ribavarin regimens on treatment‐naïve chronic hepatitis C patients in Taiwan. The Kaohsiung Journal of Medical Sciences. 33(1). 44–49. 9 indexed citations
6.
Yu, Ming‐Lung, Ming‐Lun Yeh, Pei‐Chien Tsai, et al.. (2015). Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C. Medicine. 94(13). e690–e690. 75 indexed citations
7.
Yeh, Ming‐Lun, Ming‐Yen Hsieh, Ching‐I Huang, et al.. (2015). Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin. Medicine. 94(42). e1837–e1837. 11 indexed citations
8.
Dai, Chia‐Yen, Ming‐Lun Yeh, Meng‐Hsuan Hsieh, et al.. (2013). Association between gallbladder stones and chronic hepatitis C: Ultrasonographic survey in a hepatitis C and B hyperendemic township in Taiwan. The Kaohsiung Journal of Medical Sciences. 29(8). 430–435. 8 indexed citations
9.
Chen, Chun‐Hao, Jee‐Fu Huang, Chung‐Feng Huang, et al.. (2012). Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. Hepatology International. 7(1). 162–170. 4 indexed citations
10.
11.
Dai, Chia‐Yen, Wan‐Long Chuang, Ming‐Yen Hsieh, et al.. (2009). Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. Antiviral Research. 85(2). 396–402. 15 indexed citations
12.
Huang, Chung‐Feng, Jeng‐Fu Yang, Jee‐Fu Huang, et al.. (2009). Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. Journal of Gastroenterology and Hepatology. 25(4). 758–765. 22 indexed citations
13.
Dai, Chia‐Yen, Chi‐Kung Ho, Jee‐Fu Huang, et al.. (2009). Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in Taiwan. Journal of Hepatology. 52(2). 160–166. 46 indexed citations
14.
Dai, Chia‐Yen, Jee‐Fu Huang, Ming‐Yen Hsieh, et al.. (2009). Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. Journal of Hepatology. 50(4). 712–718. 122 indexed citations
15.
Dai, Chia‐Yen, Wan‐Long Chuang, Li‐Po Lee, et al.. (2008). Association between transforming growth factor-beta 1 polymorphism and virologic characteristics of chronic hepatitis C. Translational research. 152(4). 151–156. 9 indexed citations
16.
Hsieh, Meng‐Hsuan, Li‐Po Lee, Ming‐Yen Hsieh, et al.. (2007). Hepatic Steatosis and Fibrosis in Chronic Hepatitis C in Taiwan. Japanese Journal of Infectious Diseases. 60(6). 377–381. 22 indexed citations
17.
Dai, Chia‐Yen, Ming‐Lung Yu, Ming‐Yen Hsieh, et al.. (2007). Early response to lamivudine therapy in clinically non‐cirrhotic chronic hepatitis B patients with decompensation. Liver International. 27(10). 1364–1370. 8 indexed citations
18.
Hsieh, Ming‐Yen, Li‐Po Lee, Nai‐Jen Hou, et al.. (2007). Qualitative Application of COBAS AMPLICOR HCV Test Version 2.0 Assays in Patients with Chronic Hepatitis C Virus Infection and Comparison of Clinical Performance with Version 1.0. The Kaohsiung Journal of Medical Sciences. 23(7). 332–338. 4 indexed citations
19.
Dai, Chia‐Yen, Wan‐Long Chuang, Ming‐Yen Hsieh, et al.. (2007). Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Research. 75(2). 146–151. 16 indexed citations
20.
Dai, Chia‐Yen, Wan‐Long Chuang, Shinn‐Cherng Chen, et al.. (2005). Tumor Necrosis Factor–α Promoter Polymorphism at Position −308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection. The Journal of Infectious Diseases. 193(1). 98–101. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Valeria Piazzolla Breakdown of academic impact, for papers by Li‐Po Lee Breakdown of academic impact, for papers by Hung‐Da Tung Breakdown of academic impact, for papers by Annarosa Cussigh Breakdown of academic impact, for papers by Sara Cmet Breakdown of academic impact, for papers by Jennifer E. Layden‐Almer Breakdown of academic impact, for papers by Elisabetta Degasperi Breakdown of academic impact, for papers by Guido Colloredo Breakdown of academic impact, for papers by R. Soffredini Breakdown of academic impact, for papers by Elisa Fumolo
Rankless by CCL
2026